Dupixent Phase 3 data showed significant histological remission of eosinophilic esophagitis
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
There is also a growing interest in whole generation sequencing (WGS)
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Olympus Corp was the market leader for endoscopy devices, accounting for around 23% of the global market in 2021.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Subscribe To Our Newsletter & Stay Updated